Presbyopia lens launch

Article

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

The main feature of this multifocal lens is its aspheric multi-curve design comprising a segment shaped near-vision section characterized by seamless transitions between the near and far vision zones.

Various benefits for the patient are said to result from this innovative design. In particular, reflections and image jumps as usually in twilight light conditions or in central headlight glare conditions will no longer occur. Furthermore the MIOL is pupil independent, offers true +3 D addition and ensures a minimal loss of light.

A multi-center study conducted under the leadership of Professor G. U. Auffarth of Heidelberg University Eye Clinic analyzed the results obtained by the implantation of the lens in 114 eyes of 69 patients (mean age: 68 ± 12 years). Oculentis says this confirmed the functional outcomes achieved with the MIOL as well as a very high degree of patient satisfaction. No complications were seen in both, unilateral and bilateral implantation. Mean IOL power came to 21.00 ± 2.01 D Three months after surgery, a best corrected distance visual acuity of 0.01 ± 0.14 logMAR was measured. Uncorrected near visual acuity came to 0.08 ± 0.17 logMAR.

Using the computer-controlled SML technology, each LENTIS Mplus IOL will be customized to the special needs of the individual patient and is made from the well-proved HydroSmart material.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.